Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) will likely be posting its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.0550) per share and revenue of $8.33 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.
Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.03. On average, analysts expect Black Diamond Therapeutics to post ($0.57) EPS for the current fiscal year and ($1.03) EPS for the next fiscal year.
Black Diamond Therapeutics Trading Down 1.7%
Shares of NASDAQ BDTX opened at $1.75 on Tuesday. The business’s fifty day simple moving average is $1.94 and its 200-day simple moving average is $2.19. Black Diamond Therapeutics has a 12-month low of $1.60 and a 12-month high of $4.94.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the company. Raymond James Financial reaffirmed an “outperform” rating on shares of Black Diamond Therapeutics in a research report on Thursday, August 6th. Wall Street Zen raised Black Diamond Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Black Diamond Therapeutics in a research note on Friday, October 9th. TD Cowen reaffirmed a “buy” rating on shares of Black Diamond Therapeutics in a report on Thursday, August 6th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Black Diamond Therapeutics in a research note on Thursday, August 6th. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Black Diamond Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $11.00.
Check Out Our Latest Stock Analysis on Black Diamond Therapeutics
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company uses its proprietary MasterKey platform to identify and develop small-molecule therapies designed to address oncogenic mutations across multiple tumor types, including alterations that may be difficult to target with conventional approaches.
Black Diamond’s pipeline has included brain-penetrant therapies for cancers affecting the central nervous system.
Read More
- Five stocks we like better than Black Diamond Therapeutics
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
